AlphAIAlphAI — Financial news for AI agents
clinicaltrialsarena.com

Faeth’s combo posts mid-stage refractory endometrial cancer win

Faeth Therapeutics' Phase II trial of PIKTOR (serabelisib and sapanisertib) with paclitaxel showed 33% objective response in 36 evaluable patients with advanced endometrial cancer and PAM pathway mutations. Median progression-free survival was 7.4 months, with 62% of patients progression-free at six months. The company plans Phase III trials. According to GlobalData, endometrial cancer clinical trial initiations increased 37% from 2020 to 2025.

Original reporting
clinicaltrialsarena.com
Published Nov 9, 2026, 2:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 3:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$FTH
Relevance
8/10
AlphAI data visualization · based on clinicaltrialsarena.com
Decision brief

The 30-second read

Med
01

Why it matters

The data show a 33% objective response rate and median PFS of 7.4 months, suggesting a promising therapeutic option.

02

Market read

First disclosure of Phase II outcomes could affect Faeth's valuation and the broader oncology biotech sector.

03

What to watch

Potential competition from Merck/Kelun ADC and upcoming regulatory scrutiny.

Relevance 8/10Novelty 8/10Timing: today

Background

Faeth Therapeutics reported Phase II results for its PIKTOR combo in advanced endometrial cancer.

Market effects

Sector

Positive Phase II data may boost investor interest in endometrial‑cancer biotech space.

Regional

Limited to US‑listed biotech investors; no broad regional effect.

Global

Modest, as trial results could influence global oncology pipelines.

Counterpoint

What could challenge this read

Trial size is small and single‑arm; results may not translate to Phase III success.

Key entities

  • Company
    Faeth Therapeutics

    Biotech developing PIKTOR combo for endometrial cancer.

Read at source← All news

StoryFaeth Therapeutics reports 33% response rate in Phase 2 endometrial cancer trial

Related articles

$FTHMedAI 8/10

Baird reiterates Faeth Therapeutics stock rating on PIK-201 data

Baird reiterated an Outperform rating on Faeth Therapeutics (FTH) with a $57 price target, citing positive PIK-201 data. The stock is down 35% in a week, trading at $12.79. Analysts highlight its potential in endometrial and breast cancer, with a market cap of $333M and strong financial metrics. Recent clinical trials showed a 33% response rate in endometrial cancer.

investing.com
$FTHHighAI 8/10

Faeth Therapeutics stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating and $60 price target for Faeth Therapeutics (FTH) after positive Phase 2 trial results for PIKTOR. The trial showed a 33% objective response rate and 7.4-month median progression-free survival, outperforming typical chemotherapy benchmarks. Despite a 45% stock decline, analysts highlight the drug's potential and manageable toxicity. Other firms also reiterated positive ratings, and the company appointed a new board member.

investing.com
$FTHHighAI 8/10

Why This Recently Rebranded Biotech Just Crashed 45%

Faeth Therapeutics (FTH) shares fell over 40% after reporting that only 33% of patients responded to its experimental endometrial cancer treatment, PIK-201, combined with paclitaxel. The analysis included 36 evaluable patients, with six excluded. Investors reacted negatively to the effectiveness data.

investors.com